French drugmaker Sanofi announced on Wednesday a partnership with U.S.-based MyoKardia to develop therapies for patients with genetic heart diseases.
The collaboration includes up to $200 million in equity investments, milestone payments, and research and development services through 2018, Sanofi said in a statement.
MyoKardia was founded in 2012 and is funded by healthcare investor Third Rock Ventures.
Join the Conversation